The authors present two patients with Alzheimer's disease who each received a single intravenous dose of physostigmine. Subjective complaints and mood changes were disproportional with objectively verified physiological side effects. Such observations may contribute to an understanding of affective disorders and should receive more attention in future studies of cholinesterase inhibitors.
